(Q37169716)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18494810%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

review article

1 reference

title

The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18494810%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18494810%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Hussam Abuissa

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18494810%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

publication date

20 May 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18494810%20AND%20SRC:MED&resulttype=core&format=json

Diabetes, Obesity and Metabolism

7 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18494810%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18494810%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18494810%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

1157-1166

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18494810%20AND%20SRC:MED&resulttype=core&format=json

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle-aged Japanese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Diabetes and hypertension: epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Tissue-specific nutritional regulation of angiotensinogen in adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Effect of ramipril on the incidence of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Mineralocorticoid receptor antagonism in experimental atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Aldosterone-induced vasculopathy: a new reversible cause of cardiac death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Angiotensin and insulin resistance: conspiracy theory

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

The role of angiotensin II type 1 receptor blockers in the prevention and management of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

The multi-faceted cross-talk between the insulin and angiotensin II signaling systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

The effect of prostaglandins E1, E2 and F2 alpha and indomethacin on the sensitivity of glycolysis and glycogen synthesis to insulin in stripped soleus muscles of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

The effects of valsartan on insulin sensitivity in patients with primary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Angiotensin blockade prevents type 2 diabetes by formation of fat cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Evolving strategies for renoprotection: diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

The clinical implications of aldosterone escape in congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00898.X

10.1111/J.1463-1326.2008.00898.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18494810%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference